Arylsulfatase B replacement 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Naglazyme (galsulfase) / AnGes MG, BioMarin
2007-001453-26: Natural course, effects of enzyme therapy and health economic aspects in patients with mucopolysaccharidosis type I, II and VI. Long-term folloe-up of untreated patients and patients receiving commercially available Aldurazyme, Elaprase and Naglazyme.

Ongoing
4
50
Europe
idursulfase, Naglazyme, Aldurazyme, Elaprase, Naglazyme, Aldurazyme, Elaprase, Naglazyme, Aldurazyme
Mucopolysaccharidosis type I, II and VI.
 
 
NCT05824663: A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors

Not yet recruiting
1
50
NA
HBM1020
Harbour BioMed US, Inc.
Advanced Solid Tumor
12/24
06/25
IUERT, NCT04532047: In Utero Enzyme Replacement Therapy for Lysosomal Storage Diseases

Recruiting
1
10
US
Aldurazyme (laronidase), Elaprase (idursulfase), Vimizim (elosulfase alfa), Naglazyme (galsulfase), Mepsevii (vestronidase alfa-vjbk), Lumizyme (alglucosidase alfa), Kanuma (sebelipase alfa)
University of California, San Francisco, Duke University
MPS I, MPS II, MPS IVA, MPS VI, Mps VII, Gaucher Disease, Type 2, Gaucher Disease, Type 3, Pompe Disease Infantile-Onset, Wolman Disease
07/31
07/32
SIG-020 / Eli Lilly
No trials found

Download Options